This presentation contains "forward-looking" statements which are statements relating to future events. These statements include those relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. A detailed description of these risk factors can be found under the caption “Risk Factors” in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation.

In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this presentation also contains non-GAAP financial measures. A reconciliation of these measures to the most directly comparable GAAP measures is included in the embedded hyperlink and is available on the “Investor Events” section of our investor relations website at ir.perkinelmer.com.

Guidance for future periods is provided on a non-GAAP basis and cannot be reconciled to the closest GAAP measures without unreasonable effort due to the unpredictability of the amounts and timing of events affecting the items the Company excludes from these non-GAAP measures. The timing and amounts of such events and items could be material to the Company’s results prepared in accordance with GAAP.
OUR MISSION

INNOVATING for a healthier WORLD

PASSIONATE

Dedicated to ensuring the highest quality product and keeping the consumer safe

Focused on accelerating pre-clinical discoveries and enabling customers to deliver safe and effective therapies

Passionate about saving and transforming patients’ lives

Energized by empowering a cleaner and safer environment

WHO WE ARE
**PERKINELMER TODAY**

**Portfolio Mix**

- **Americas** ~45%
- **Europe** ~30%
- **Asia** ~25%

**Consumables, Services, Software**

- ~80%

**Instruments**

- ~20%

**2021 Performance**: Continued to Deliver Record Results

- **Non-COVID Organic Growth**: 16% Vs. 2020
- **COVID Revenue**: >$1.5B
- **Adj. EPS Growth**: 30%+ Vs. 2020

**2021e revenue**: $5.0B

**Diagnostics (Dx)**

- >16,000 Employees Strong

**Discovery & Analytical Solutions (DAS)**

* YTD through 3Q'21; † Reconciliations of these non-GAAP items to GAAP are provided on our website and here (link)
WHAT YOU’LL HEAR TODAY

THE NEW PERKINELMER
Transformation Enabling Faster Growth and Greater Value Creation

1. ATTRACTIVE & EXPANDED PORTFOLIO
   Providing complete solutions across Dx and LS

2. FOCUSED INTERNAL EXECUTION
   Clear progress across four strategic priorities

3. STRONG FINANCIAL OUTLOOK
   Delivering results and improved financial profile
WHAT YOU’LL HEAR TODAY

1. ATTRACTIVE & EXPANDED PORTFOLIO
   Providing complete solutions across Dx and LS

2. FOCUSED INTERNAL EXECUTION
   Clear progress across four strategic priorities

3. STRONG FINANCIAL OUTLOOK
   Delivering results and improved financial profile
ATTRACTION & EXPANDED PORTFOLIO

TODAY’S DISCUSSION: THE BUILDING BLOCKS OF OUR SUCCESS

**DIAGNOSTICS**

- Approaching $3B
  - Global portfolio with leading franchises
- Expansion into Adjacent Markets
- Comprehensive Portfolio
- From Assays to Integrated Workflows

**LIFE SCIENCES**

- $2B+ DAS segment, with LS representing ~65% of ‘21 pro-forma revenue
- Best-in-Class Pre-Clinical Discovery
- Differentiating Cell and Gene Therapy

PKI Revenue

<table>
<thead>
<tr>
<th>Pre-2018</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>60% Dx &amp; LS</td>
<td>80%+ Dx &amp; LS</td>
</tr>
</tbody>
</table>

**Strong Core Capabilities**

- Expansion through Strategic Solutions Focus

**Expansion into Adjacent Markets**

- Comprehensive Portfolio
- From Assays to Integrated Workflows
ATTRACTIVE & EXPANDED PORTFOLIO

TODAY’S DISCUSSION: THE BUILDING BLOCKS OF OUR SUCCESS

DIAGNOSTICS

Approaching $3B global portfolio with leading franchises

- Expansion into Adjacent Markets
- Comprehensive Portfolio
- From Assays to Integrated Workflows

LIFE SCIENCES

$2B+ DAS segment, with LS representing ~65% of ‘21 pro-forma revenue

- Best-in-Class Pre-Clinical Discovery
- Differentiating Cell and Gene Therapy

PKI Revenue

Pre-2018

60% Dx & LS

2021

80%+ Dx & LS

Strong Core Capabilities

Expansion through Strategic Solutions Focus
**Diagnostics at a Glance**

**Total Addressable Market:** $35B+

**Revenue by Geography**
- **Americas:** 45%
- **Europe:** 35%
- **APAC:** 20%

**Expansion into Areas Outside Reproductive Health (RH)**
- Sales outside RH in 2015: ~30%
- Sales outside RH in 2021: ~80%

**Strong Growth**
- **DD** core revenue growth CAGR over last 5 years
- Core **HSD** organic growth outlook

**Key Positions**

1. **Overall Reproductive Solutions**
   - Solutions include newborn screening, NIPT, biochemical screening, and pre-eclampsia

2. **Autoimmune IVD**
   - Extensive menu across autoimmune, allergy, and latent tuberculosis

3. **RNA / DNA Extraction**
   - Best-in-class solutions across liquid handling and nucleic acid extraction

* YTD through 3Q'21
PROVIDING SEAMLESS DIAGNOSTICS WORKFLOWS AT SCALE

Expansion into Adjacent Markets
Expanding our Total Addressable Market to $35B with the extension into new infectious disease and autoimmune markets

Comprehensive Portfolio
Driving best-in-class detection capabilities across a full array of customer settings

From Assays to Integrated Workflows
Augmenting our detection through end-to-end automation and integrated digital tools

LEADING $2.9B DIAGNOSTICS FRANCHISE
**OUR 2021 STRATEGIC M&A EXTENDED OUR PORTFOLIO INTO ATTRACTIVE & COMPLEMENTARY NEW MARKETS**

<table>
<thead>
<tr>
<th>Expansion into Adjacent Markets</th>
</tr>
</thead>
<tbody>
<tr>
<td>Expanding our Total Addressable Market to <strong>$35B</strong> with the extension into new <strong>infectious disease and autoimmune markets</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Overview</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Recognized global leader of proprietary <strong>latent tuberculosis</strong> kits and workflows</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Transaction Date</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>March 2021</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Strategic Fit</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>• Advances <strong>infectious disease</strong> offering into new respiratory markets</td>
</tr>
<tr>
<td>• Stronger together with <strong>complete workflow</strong> solutions, enabled by faster automation and global service capabilities</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>TUBERCULOSIS</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Developer of <strong>infectious disease</strong> immunoassays and random access chemiluminescence automation</td>
</tr>
<tr>
<td><strong>March 2021</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>ENDOCRINOLOGY</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Developer of innovative immunoassays and random access chemiluminescence automation</td>
</tr>
<tr>
<td><strong>July 2021</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Strategic Fit</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>• Extends <strong>autoimmune menu</strong> and chemiluminescence assay development</td>
</tr>
<tr>
<td>• Fills gaps in <strong>random access automation</strong> (vertical integration opportunity)</td>
</tr>
</tbody>
</table>

| **2021 Dx Acquisitions Add >$150 Million of Annualized Revenue Growing Mid-Teens** |
Delivering Comprehensive Solutions for Any Lab’s Needs

Comprehensive Portfolio

Driving best-in-class detection capabilities across a full array of customers settings

Highly automated, more centralized

Explorer™ Workstation
- HIGH-PERFORMANCE MOLECULAR DX
- End-to-end automated workstream
- Best-in-class throughput
- Modular system
- 2020 LAUNCH

Accentis
- RANDOM ACCESS CHEMILUMINESCENCE
- 200 tests / hour
- 50+ parameters
- 8-hour walkaway automation
- 2022 LAUNCH

/i10
- COMPACT BENCHTOP RANDOM ACCESS CHEMILUMINESCENCE AUTOMATION
- Newest launch
- 170 tests / hour
- >60 registered assays
- 2022 LAUNCH

/iSYS
- New Through IDS
- Global install base
- >115 registered assays
- 120 tests / hour

Community and near-patient settings

SuperFlex™ (CE-IVD)
- CHEMILUMINESCENT IMMUNOASSAY SYSTEM
- 15-minute turnaround time
- Hands-free processing
- One-click operation
- 2019 LAUNCH
From Assays to Integrated Workflows

Augmenting our detection through end-to-end automation and integrated digital tools

Example Offerings across Workflow

... with significant increase in installed based and new integrated digital tools

Digitally-enabled through PKeye™ Mobile Lab Operations Monitor
**In Action: Complementing Our Leading Latent TB Test Through Vertical Workflow Integration**

**Example**

**Tuberculosis**

#1 most deadly infectious disease over the past decade

**T-SPOT.TB**

**From Assays to Integrated Workflows**

#2 player in latent TB IGRA testing globally …

**Now Bringing Additional Value to Our Customers Through PKI’s Complete Workflow & Services**

**Reagent Programs:** leveraging high-quality, internal sources

**Automation Programs:** driving integrated customer solutions at a range of throughputs, enabling faster automation

**NEW**

- chemagic™ nucleic acid extraction
- Nexcelom Celigo image cytometer
- Euroimmun plate reader

**Today:** JANUS™ liquid handler

**Tomorrow:** explorer™ workstation

… complemented through **cross-portfolio synergies** and **service capabilities** to offer **complete solutions** for our customers

**Tuberculosis**

#1 most deadly infectious disease over the past decade

**T-SPOT.**

**From Assays to Integrated Workflows**

#2 player in latent TB IGRA testing globally …

**Now Bringing Additional Value to Our Customers Through PKI’s Complete Workflow & Services**

**Reagent Programs:** leveraging high-quality, internal sources

**Automation Programs:** driving integrated customer solutions at a range of throughputs, enabling faster automation

**NEW**

- chemagic™ nucleic acid extraction
- Nexcelom Celigo image cytometer
- Euroimmun plate reader

**Today:** JANUS™ liquid handler

**Tomorrow:** explorer™ workstation

… complemented through **cross-portfolio synergies** and **service capabilities** to offer **complete solutions** for our customers
DIAGNOSTICS SUMMARY: LEADING POSITIONS IN KEY MARKETS

Expansion into Adjacent Markets
Comprehensive Portfolio
From Assays to Integrated Workflows

Strong +HSD Growth Outlook

>$2B deployed capital since 2015
Nearly Tripled Core Dx revenue since 2015
**ATTRACTIVE & EXPANDED PORTFOLIO**

**TODAY’S DISCUSSION: THE BUILDING BLOCKS OF OUR SUCCESS**

**DIAGNOSTICS**
- Strong Core Capabilities
- Approaching $3B global portfolio with leading franchises
- Expansion into Adjacent Markets
- Comprehensive Portfolio
- From Assays to Integrated Workflows

**LIFE SCIENCES**
- $2B+ DAS segment, with LS representing ~65% of ‘21 pro-forma revenue
- Best-in-Class Pre-Clinical Discovery
- Differentiating Cell and Gene Therapy

---

**PKI Revenue**

- **Pre-2018**
  - 60% Dx & LS

- **2021**
  - 80%+ Dx & LS
**DISCOVERY & ANALYTICAL SOLUTIONS AT A GLANCE**

**Total Addressable Market:** $35B+

**Life Sciences:** $2.1B (2021e revenue)

**REVENUE BY GEOGRAPHY**
- **AMERICAS:** 40%
- **EUROPE:** 30%
- **APAC:** 30%

**LS REVENUE IN DAS**
- <45% in 2015 vs. ~65% in 2021*

**ACCELERATED GROWTH**
- 2% in '14 – '16
- 5% in '17 – '19
- ~7-9% in '23+

**KEY POSITIONS**

**#1 PRE-CLINICAL IMAGING**
- Best-in-class overall pre-clinical workflow utilizing multi'omics

**#2 FLOW CYTOMETRY REAGENTS**
- Solutions across flow, fluorescence, and luminescence technologies

**#2 TRANSLATIONAL RESEARCH & CLINICAL INFORMATICS**

**#1 TOP-20 PHARMA SERVICES PROVIDER** with broadest set of offerings

---

* Pro-Forma 2021; ** YTD through 3Q’21
Leveraging our attractive existing and expanded positions in Biologics into Cell and Gene Therapy

Scaling end-to-end solutions which help close the chasm from Research to Clinic

Differentiating Cell and Gene Therapy

$700M reagents franchise with sustainable double-digit growth

Leveraging our attractive existing and expanded positions in Biologics into Cell and Gene Therapy

Best-in-Class Pre-Clinical Discovery

COMPLEMENTING OUR CORE WITH UNIQUE CAPABILITIES ADDRESSING OUR CUSTOMERS’ MOST ACUTE NEEDS

STRONG LIFE SCIENCES FOUNDATION

✓ Category leadership in pre-clinical imaging
✓ Leading suite of detection products
✓ Novel molecular & cell biology products
## Scaling Our Strategic Focus Areas

<table>
<thead>
<tr>
<th>Best-in-Class Pre-Clinical Discovery</th>
<th>Differentiating Cell and Gene Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BioLegend®</strong>&lt;br&gt;Enabling Legendary Discovery™&lt;br&gt;Global developer and manufacturer of high-quality antibodies and reagents&lt;br&gt;September 2021&lt;br&gt;• Key content development engine across PKI&lt;br&gt;• Adds global scale to research reagents portfolio</td>
<td><strong>horizon</strong>&lt;br&gt; Designs and engineers genetically modified cells for research &amp; clinical applications&lt;br&gt;December 2020&lt;br&gt;• Adds leading functional genomics capabilities&lt;br&gt;• Agile innovator in CRISPR &amp; base editing</td>
</tr>
</tbody>
</table>

Represents Nearly $500M of 2021 Annualized Revenue Growing Mid-Teens+
UNIQUELY POSITIONED ACROSS THE PHARMA DISCOVERY WORKFLOW

Best-in-Class Pre-Clinical Discovery

Solutions for Pharma / Biotech at every stage of the Discovery process

Increasing our customers’ Speed to market
  ✓ Productivity
  ✓ Success rate

Tools to Feed the Biomarker Pipeline

Biomarker Development

Detection reagents
Plate readers

High Content imagers and reagents

✓ Improved target identification

✓ Driving more relevant disease models

Pre-Clinical

In vivo imaging

✓ Enabling dynamic phenotypic readouts

Accelerated drug development by creating a clinical environment in a pre-clinical state

Functional Genomics

Antibody Content Development

First-in-Harmonized Discovery Workflow

Well
Cell
Animal

Seamless automation, robotics and informatics across each step

Best-in-Class Pre-Clinical Discovery
A COMPELLING END-TO-END SOLUTION FOR CELL & GENE THERAPY CUSTOMERS

Differentiating Cell & Gene Therapy

Offering a complete solution
✓ Tools for early-stage optimization of therapies
✓ Enabling reduction of development timeline from Years to Months

Differentiated Customer Offering: Rare Disease or Oncology

Gene Modulation and Editing

Genetic Material: “Payload”

Delivery System: Viral Vectors

QA / QC: Therapies

Leading functional genomics tools to understand impact to human cells

Tools include SMARTvector, base editing, and CRISPR

Portfolio of viral vectors and continuing to fill gaps

Premier cell analysis tools being standardized into customer workflows

Gene Modulation

Genetic Material

Delivery System

QA / QC: Therapies

PKI

Offering

horizon

SIRION BIOTECH

Nexcelom
Our Differentiated Life Sciences Expansion Further Bridges into Diagnostics

LIFE SCIENCES
- Pre-clinical biomarkers
- Cell & Gene Therapy workflows
- Accelerates new product development, enabling our customers to deliver faster, better therapies

DIAGNOSTICS
- IVD Kits
- T-Cell Services
- Novel Neuro Assays

Strong Life Sciences Foundation
- Differentiated capabilities
- Strong customer alignment to drive sustainable growth

New Content Development Engine
- Antibodies
- Recombinant Proteins
DAS SUMMARY: CAPITALIZING ON STRONG LIFE SCIENCES PORTFOLIO

- Portfolio Expansion Enables Best-In-Class Pre-Clinical Discovery
- Building a Foundation in Cell & Gene Therapy
- New Content Development Drives Rapid Innovation

Driving shift from MSD to SUSTAINABLE HSD GROWTH

LIFE SCIENCES REVENUE IN DAS

<45% vs. ~65%

<45% in 2015 vs. ~65% Pro forma 2021

~$0.7B LS reagents franchise growing DOUBLE DIGITS
WHAT YOU’LL HEAR TODAY

1. ATTRACTION & EXPANDED PORTFOLIO
   Providing complete solutions across Dx and LS

2. FOCUSED INTERNAL EXECUTION
   Clear progress across four strategic priorities

3. STRONG FINANCIAL OUTLOOK
   Delivering results and improved financial profile

THE NEW PERKINELMER
Transformation Enabling Faster Growth and Greater Value Creation
FOCUSED INTERNAL EXECUTION ACROSS OUR STRATEGIC PRIORITIES

TECHNOLOGY & INNOVATION

✓ Global Agility
✓ Customer-Centric

➢ *Investing in New Frontiers:* NPI launches up 15% in 2021

COMMERCIAL EXECUTION

✓ Efficiency
✓ Customer Experience

➢ *Channel Excellence:* >75% eCommerce revenue growth in 2021

OPERATIONAL EXCELLENCE

✓ Cost-out
✓ FCF Conversion
✓ Total Quality

➢ *Acquisition Integration:* approach has been vital to early successes

TALENT & CULTURE

✓ Investing in Our Talent
✓ Engaged with Shared Core Values

➢ *Advancing against ESG Goals:* progress across 4 pillars

Additional information on following slides
OPERATIONAL EXCELLENCE: OUR FLEXIBLE INTEGRATION APPROACH HAS BEEN VITAL TO OUR EARLY SUCCESSES

Putting SCIENCE & PEOPLE first

No “One Size Fits All” Formula
Prioritized Employee Experience
Frequent Stakeholder Engagement

Stronger Together
Recent Acquisitions Delivered \textgreater 20\% Pro-Forma Revenue Growth in 2021
# Talent and Culture: Making Initial Progress on Key ESG Goals

<table>
<thead>
<tr>
<th>Emissions Reduction</th>
<th>Stated Goal</th>
<th>Progress</th>
</tr>
</thead>
<tbody>
<tr>
<td>30% reduction of Scope 1 &amp; 2 Emissions by 2030 (vs. 2019) and net carbon neutrality by 2040</td>
<td>Decreased 2020 Scope 1 and 2 Emissions by 8.5%</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Waste Reduction</th>
<th>Stated Goal</th>
<th>Progress</th>
</tr>
</thead>
<tbody>
<tr>
<td>Achieve 15% reduction in non-hazardous / non-recyclable waste going to landfills by 2025</td>
<td>5 tons of lab equipment, 122 tons of packaging materials, and 20 kilograms of batteries collected and recycled</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Employee Satisfaction</th>
<th>Stated Goal</th>
<th>Progress</th>
</tr>
</thead>
<tbody>
<tr>
<td>Consistent employee satisfaction &gt;75% and reduce voluntary turnover to less than industry average (currently ~10%)</td>
<td>7.8 / 10 employee engagement score for employee motivation, commitment, and connection to the company</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Diversity &amp; Inclusion</th>
<th>Stated Goal</th>
<th>Progress</th>
</tr>
</thead>
<tbody>
<tr>
<td>Increase female representation in leadership positions to 40% by 2025</td>
<td>45% YTD leadership positions have been filled by female candidates</td>
<td></td>
</tr>
</tbody>
</table>
WHAT YOU’LL HEAR TODAY

1. ATTRACTIVE & EXPANDED PORTFOLIO
   Providing complete solutions across Dx and LS

2. FOCUSED INTERNAL EXECUTION
   Clear progress across four strategic priorities

3. STRONG FINANCIAL OUTLOOK
   Delivering results and improved financial profile

THE NEW PERKINELMER
Transformation Enabling Faster Growth and Greater Value Creation
ELEVATING OUR 2023 FORECAST VS 6 MONTHS AGO

REVENUE
- June 2021: $4.0B+
- Today: $6.50+

CORE ORGANIC GROWTH
- June 2021: 5-7%
- Today: 23%

OPERATING MARGIN
- June 2021: 23%
- Today: 23%

ADJ. EPS
- June 2021: $6.50+
- Today: $6.50+

Expect to de-lever to < 3.0x by mid-2023

Note: Figures assume $100M of COVID-19 related revenues, 18% tax rate, and 127M shares outstanding in 2023
ELEVATING OUR 2023 FORECAST VS 6 MONTHS AGO

REVENUE
- June 2021: $4.0B+
- Today: $4.5B+

CORE ORGANIC GROWTH
- June 2021: 5-7%
- Today: 23%

OPERATING MARGIN
- June 2021: 23%
- Today: $6.50+

ADJ. EPS
- June 2021: $6.50+
- Today: $6.50+

Expect to de-lever to < 3.0x by mid-2023

Note: Figures assume $100M of COVID-19 related revenues, 18% tax rate, and 127M shares outstanding in 2023
ELEVATING OUR 2023 FORECAST VS 6 MONTHS AGO

- **Revenue**
  - June 2021: $4.0B+
  - Today: $4.5B+

- **Core Organic Growth**
  - June 2021: 5-7%
  - Today: 7-9%

- **Operating Margin**
  - June 2021: 23%
  - Today: 23%

- **ADJ. EPS**
  - June 2021: $6.50+
  - Today: $6.50+

**Expect to de-lever to < 3.0x by mid-2023**

**Note:** Figures assume $100M of COVID-19 related revenues, 18% tax rate, and 127M shares outstanding in 2023.
ELEVATING OUR 2023 FORECAST VS 6 MONTHS AGO

Expect to de-lever to < 3.0x by mid-2023

Note: Figures assume $100M of COVID-19 related revenues, 18% tax rate, and 127M shares outstanding in 2023
ELEVATING OUR 2023 FORECAST VS 6 MONTHS AGO

<table>
<thead>
<tr>
<th>REVENUE</th>
<th>June 2021</th>
<th>Today</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$4.0B+</td>
<td>$4.5B+</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CORE ORGANIC GROWTH</th>
<th>June 2021</th>
<th>Today</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>5-7%</td>
<td>7-9%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>OPERATING MARGIN</th>
<th>June 2021</th>
<th>Today</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>23%</td>
<td>26%+</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ADJ. EPS</th>
<th>June 2021</th>
<th>Today</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$6.50+</td>
<td>$7.00+</td>
</tr>
</tbody>
</table>

Expect to de-lever to < 3.0x by mid-2023

Note: Figures assume $100M of COVID-19 related revenues, 18% tax rate, and 127M shares outstanding in 2023
**The New PerkinElmer 2023+ Profile**

*Transformed the business ...*

- **Attractive & Expanded Portfolio**: Providing complete solutions across Dx and LS.
- **Focused Internal Execution**: Clear progress across our four strategic priorities.

*... to deliver compounding growth, strong margins, and cashflow, enabling EPS growth*

**Financial Trajectory**

- **Organic Growth**: HSD
- **Margin Expansion**: 50-75 bps / year
- **Adj. EPS Growth (without capital deployment)**: >10%
Innovating for a healthier world

ONE MISSION

Countless Opportunities